| Literature DB >> 35497891 |
Marina M Tabbara1,2, Giselle Guerra3,2, Juliano Riella1,2, Phillipe Abreu1,2, Angel Alvarez2, Rodrigo Vianna1,2, Linda Chen1,2, Mahmoud Morsi1,2, Jeffrey J Gaynor1,2, Javier Gonzalez4, Gaetano Ciancio1,2,5.
Abstract
Background: Multiple renal arteries (MRA) are often encountered during living-donor kidney transplantation (LDKT), requiring surgeons to pursue complex renovascular reconstructions prior to graft implantation. With improvements in reconstruction and anastomosis techniques, allografts with MRA can be successfully transplanted with similar outcomes to allografts with a single renal artery. Here, we describe in detail various surgical techniques for reconstruction of MRA grafts with the intent of creating a single arterial inflow.Entities:
Keywords: kidney allografts; living donors; multiple renal blood vessels; renal transplantation; surgical innovation
Mesh:
Year: 2022 PMID: 35497891 PMCID: PMC9046561 DOI: 10.3389/ti.2022.10212
Source DB: PubMed Journal: Transpl Int ISSN: 0934-0874 Impact factor: 3.842
FIGURE 1Conjoined anastomosis techniques. (A) Single ostium side-to-side anastomosis. (B) Single ostium side-to-side-to-side anastomosis.
FIGURE 2Techniques for grafting a main RA and an accessory pole artery. (A) UPRA anastomosed end-to-side to main RA. (B) LPRA anastomosed end-to-side to main RA. (C) Short UPRA anastomosed end-to-side to a branch of the main RA. (D) Short LPRA anastomosed end-to-side to a branch of the main RA. (E) Short LPRA anastomosed end-to-side to a branch of the main RA inside the hilum.
FIGURE 3Creation of a single inflow orifice for grafts with 3RA. (A) Two main RA conjoined side-to-side and UPRA anastomosed end-to-side to the upper main RA. (B) LPRA conjoined in a single lumen with the main RA, and short middle RA anastomosed end-to-side to the upper branch of the main RA. (C) Two RA conjoined side-to-side in a single lumen and short UPRA anastomosed end-to-side to a branch of the upper renal artery inside the hilum. (D) Short UPRA anastomosed end-to-side to a branch of the main RA inside the hilum, and the LPRA was anastomosed end-to-side to main RA.
FIGURE 6(A) LPRA (white arrow) anastomosed side-to-side the main RA with 8–0 Prolene, middle RA anastomosed end-to-side to the main RA (black arrow) with 8–0 Prolene. (B) LPRA (white arrow) anastomosed end-to-side to the main RA with 8–0 Prolene. The UPRA was short, so it was anastomosed end-to-side to one of the branches of the main RA inside the hilum. (C) UPRA anastomosed end-to-end to the donor gonadal vein with 8–0 Prolene, then end-to-side with 8–0 Prolene to the main RA (white arrow). The 2 RA were conjoined side-to side with 8–0 Prolene (black arrow).
FIGURE 4Creation of two separate anastomoses for implantation. (A) Short LPRA (8 cm from the main RA) anastomosed end-to-end to the recipient inferior epigastric artery. (B) Two RA were conjoined in a single lumen and the LPRA (7 cm from the 2 RA) anastomosed end-to-end to the recipient ipsilateral inferior epigastric artery.
FIGURE 5Interposition grafting. (A) Segment of recipient inferior epigastric artery anastomosed end-to-end to the short UPRA, and then anastomosed side-to-side to the main RA. (B) Segment of recipient inferior epigastric artery anastomosed end-to-end to the short UPRA, and then anastomosed end-to-side to the main RA. (C) Segment of recipient internal iliac artery anastomosed end-to-end to the two main RA, and the short UPRA anastomosed end-to-side to one of the main RA. (D) Segment of deceased donor external iliac artery anastomosed end-to-end to two short RA conjoined in a single lumen. (E) Short UPRA extended with a segment of donor gonadal vein, then anastomosed end-to-side to the one of the 2 main RA that were conjoined in single ostium.
Distributions of recipient and donor demograpghics and of recipient operative data.
| Baseline variable | Mean ± SE if continuous (geometric mean ± SE for variables with skewed distributions); Percentage with characteristic if categorical |
|---|---|
| Recipient age (year) | 47.2 ± 1.9 (N = 73) |
| — | (Median = 48.8, Range: 2.3–77.1) |
| Recipient age (year) | — |
| <18 | 6.8% (5/73) |
| ≥18, <50 | 43.8% (32/73) |
| ≥50 | 49.3% (36/73) |
| Recipient Gender | — |
| Female | 32.9% (24/73) |
| Male | 67.1% (49/73) |
| Recipient race/Ethnicity | — |
| Black (non-Hispanic) | 12.3% (9/73) |
| Hispanic | 42.5% (31/73) |
| White (non-Hispanic) | 41.1% (30/73) |
| Other | 4.1% (3/73) |
| Recipient BMI (kg/m2) | 26.3 ± 0.7 ( |
| (Median = 26.0, Range: 16.0–42.4) | |
| Recipient pretransplant diabetes mellitus | — |
| No | 76.7% (56/73) |
| Yes | 23.2% (17/73) |
| Retransplant | — |
| No | 93.2% (68/73) |
| Yes | 6.8% (5/73) |
| Donor type | — |
| Living related | 57.5% (42/73) |
| Living unrelated | 42.5% (31/73) |
| Kidney | — |
| Left | 94.5% (69/73) |
| Right | 5.5% (4/73) |
| Number of Donor arteries | — |
| 2 | 83.6% (61/73) |
| 3 | 16.4% (12/73) |
| JP drain placed | — |
| No | 79.5% (58/73) |
| Yes | 20.5% (15/73) |
| Double-J ureteral stent placed | — |
| No | 95.9% (70/73) |
| Yes | 4.1% (3/73) |
| Total Operative Time (min) | 309.2 ± 8.1 ( |
| — | (Median = 296, Range: 206–483) |
| CIT (min) | 77.8 ± 2.9 ( |
| — | (Median = 73, Range: 15–190) |
| WIT (min) | 28.2 ± 0.6 ( |
| — | (Median = 27, Range: 20–42) |
| WIT single anastomosis (min) | 28.1 ± 0.6 ( |
| — | (Median = 27, Range: 20–42) |
| WIT two anastomosis (min) | 29.3 ± 2.8 ( |
| — | (Median = 31.5, Range: 21–33) |
| EBL (ml) | 37.9 */1.09 ( |
| — | (Median = 40.0, Range: 10–300) |
Types of reconstruction.
| 2 RA ( | N (%) |
|---|---|
| None | 3 (4.9%) |
| Conjoined, side-to-side ( | 43 (70.4%) |
| Accessory pole RA end-to-side to main RA ( | 7 (11.5%) |
| Accessory pole RA end-to-side to branch of main RA ( | 2 (3.3%) |
| Accessory RA end-to-side to branch of main RA inside the hilum ( | 1 (1.5%) |
| UPRA end-to-end to Recipient IEA, | 4 (6.6%) |
| 2 conjoined RA end-to-end to a segment of Deceased Donor EIA | 1 (1.5%) |
|
| |
| Accessory pole <1 mm ligated, 2 remaining RA conjoined side-to-side ( | 1 (1.5%) |
| Conjoined, side-to-side-to-side ( | 4 (36.4%) |
| 2 RA conjoined, UPRA end-to-side to main RA ( | 1 (8.3%) |
| LPRA and main RA conjoined, middle RA end-to-side to upper branch of main RA ( | 1 (8.3%) |
| 2 RA conjoined side-to-side, UPRA end-to-side to branch of upper RA inside the hilum ( | 1 (8.3%) |
| LPRA end-to-side to main RA, UPRA end-to-side to branch of RA inside the hilum ( | 1 (8.3%) |
| 2 RA conjoined, and LPRA end-to-end to recipient IEA | 1 (8.3%) |
| 2 main RA end-to-end to a segment of Recipient IIA, then UPRA end-to-side to one of the main RA ( | 1 (8.3%) |
| UPRA end-to-end to a segment of Donor gonadal vein, | 1 (8.3%) |
Two separate anastomosis.
Interposition grafting.
Abbreviations: IEA = inferior epigastric artery; EIA = external iliac artery; UPRA= upper pole renal artery; LPRA = lower pole renal artery; IIA = internal iliac artery.
Recipient outcomes.
| Outcome variable | Mean ± SE if continuous (geometric mean ± SE for variables with skewed distributions); Percentage with characteristic if categorical |
|---|---|
| Length of hospital stay (days) | 4.71 ± 1.06 ( |
| — | (Median = 4, Range: 3–67) |
| Developed delayed graft function (DGF) | — |
| No | 100.0% (73/73) |
| Yes | 0.0% (0/73) |
| Developed a post-operative complication (vascular, urological, or surgical) (within 12 months post-transplant) | — |
| No | 97.3% (71/73) |
| Yes | 2.7% (2/73) |
| — | |
| Serum Cr at DOT (mg/dl) | 6.9 ± 1.07 ( |
| — | (Median = 6.0, Range: 0.9–22.6) |
| Serum Cr at 3 months post-tx (mg/dl) | 1.1 ± 1.04 ( |
| — | (Median = 1.1, Range: 0.25–2.0) |
| Serum Cr at 6 months post-tx (mg/dl) | 1.1 ± 1.04 ( |
| — | (Median = 1.1, Range: 0.3–2.0) |
| Serum Cr at 12 months post-tx (mg/dl) | 1.2 ± 1.05 (N = 60) |
| — | (Median = 1.1, Range: 0.3–4.9) |
| eGFR at 3 months post-tx (ml/min/1.73 m2) | 78.4 ± 3.4 ( |
| — | (Median = 76.8, Range: 34.8–234.5) |
| eGFR at 6 months post-tx (ml/min/1.73 m2) | 76.5 ± 3.3 ( |
| — | (Median = 74.2, Range: 38.2–217.2) |
| eGFR at 12 months post-tx (ml/min/1.73 m2) | 76.2 ± 3.7 ( |
| — | (Median = 70.9, Range: 15.6–216.5) |
| eGFR at 36 months post-tx (ml/min/1.73 m2) | 66.8 ± 4.2 ( |
| — | (Median = 66.6, Range: 12.0–114.0) |
| eGFR at 60 months post-tx (ml/min/1.73 m2) | 62.6 ± 6.2 ( |
| — | (Median = 67.5, Range: 6.2–107.7) |
| Graft failure, (i.e., return to permanent dialysis or retransplanted) (as of the Last follow-up date) | — |
| No | 98.6% (72/73) |
| Yes | 1.4% (1/73) |
| Death with a functioning graft (as of the last follow-up date) | — |
| No | 93.2% (68/73) |
| Yes | 6.8% (5/73) |
| Graft Loss (death uncensored) (as of the last follow-up date) | — |
| No | 91.8% (67/73) |
| Yes | 8.2% (6/73) |
Among the 2 patients who developed a post-operative complication during the first 12 months post-transplant, the following complications were observed: acute respiratory distress syndrome (ARDS) (N = 1), and C. difficile colitis/sepsis (N = 1).
The date of last follow-up for this study was 31 July 2021. Median follow-up among 67 patients who were alive with a functioning graft as of the last follow-up date was 30.4 (range: 0.3–151.2) months post-transplant. The single cause and time-to-graft failure (return to permanent dialysis) was as follows (listed chronologically by time to graft failure): Acute TCMR, at 41.8 months post-transplant. The 5 causes of death with a functioning graft and times-to-death were as follows: Cardiovascular Event in 2 patients (at 4.4- and 7.9-months post-transplant, respectively), Infection in 2 patients (death due to C. difficile colitis/sepsis in 1 patient at 0.8 months post-transplant, and death due to infection/sepsis in 1 patient at 125.2 months post-transplant), and Ruptured Aortic Aneurysm in 1 patient (at 5.2 months post-transplant).